# PNMA5

## Overview
PNMA5 is a gene that encodes the protein PNMA family member 5, which is part of the paraneoplastic Ma (PNMA) family. This protein is implicated in various cellular processes, particularly in the context of cancer biology. PNMA5 is involved in the regulation of cancer progression and metastasis, notably in non-small-cell lung cancer (NSCLC) where it acts as a downstream target of BMP2 signaling, facilitating bone metastasis through enhanced cell migration, invasion, and osteoclast differentiation (Huang2021PNMA5). Additionally, PNMA5 interacts with other proteins such as MOAP1 to modulate chemo-sensitivity, indicating its potential role in enhancing the efficacy of chemotherapy (Su2022Revealing). Beyond NSCLC, PNMA5 has been associated with prognostic outcomes in glioblastoma and colon cancer, suggesting its utility as a biomarker for cancer prognosis (Zhou2019Candidate; Wang2020Bioinformatic).

## Clinical Significance
PNMA5 has been implicated in various cancers, particularly in the context of metastasis. In non-small-cell lung cancer (NSCLC), PNMA5 is a downstream target of BMP2 signaling, which enhances bone metastasis. Overexpression of PNMA5 promotes cell migration, invasion, and osteoclast differentiation, contributing to the progression of bone metastases. Conversely, knocking down PNMA5 can block BMP2-induced migration and invasion, suggesting its potential as a therapeutic target in NSCLC bone metastases (Huang2021PNMA5).

In glioblastoma, PNMA5 has been identified as a unique mRNA associated with overall survival prognosis. Although bioinformatics analysis suggested its involvement, RT-qPCR validation showed that PNMA5 mRNA expression was significantly downregulated in glioblastoma samples compared to controls, indicating a complex role in glioblastoma prognosis that requires further investigation (Wang2020Bioinformatic).

PNMA5 is also part of a prognostic signature in colon cancer, where it is used to predict overall survival. This signature helps classify patients into high-risk and low-risk groups, highlighting its potential as a biomarker for prognosis in colon cancer (Zhou2019Candidate).

## Interactions
PNMA5, a member of the PNMA family, is involved in several interactions that influence cancer progression and metastasis. In the context of non-small-cell lung cancer (NSCLC), PNMA5 is a downstream target of BMP2 signaling. This interaction is crucial for promoting bone metastasis, as BMP2 signaling induces the upregulation of PNMA5 mRNA and protein levels. The mechanism involves Smad1/5 binding to specific motifs in the PNMA5 promoter region, leading to its upregulation. This interaction enhances NSCLC cell migration, invasion, and osteoclast differentiation, which are critical for bone metastasis (Huang2021PNMA5).

PNMA5 also interacts with MOAP1, another member of the PNMA family, to enhance chemo-sensitivity in cancer cells. In MCF-7 cells, the co-expression of PNMA5 and MOAP1 significantly increases the sensitivity to Etoposide treatment, suggesting a synergistic interaction that enhances the effectiveness of chemotherapy (Su2022Revealing).

These interactions highlight PNMA5's role in cancer progression and its potential as a therapeutic target, particularly in the context of NSCLC bone metastasis and chemotherapy sensitization.


## References


[1. (Zhou2019Candidate) Yiming Zhou, Yiwen Zang, Yi Yang, Jianbin Xiang, and Zongyou Chen. Candidate genes involved in metastasis of colon cancer identified by integrated analysis. Cancer Medicine, 8(5):2338–2347, March 2019. URL: http://dx.doi.org/10.1002/cam4.2071, doi:10.1002/cam4.2071. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/cam4.2071)

[2. (Huang2021PNMA5) Fei Huang, Yaqiang Cao, Caihong Wang, Ruilong Lan, Bing Wu, Xianhe Xie, Jinsheng Hong, Lengxi Fu, and Gui Wu. Pnma5 promotes bone metastasis of non-small-cell lung cancer as a target of bmp2 signaling. Frontiers in Cell and Developmental Biology, May 2021. URL: http://dx.doi.org/10.3389/fcell.2021.678931, doi:10.3389/fcell.2021.678931. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.678931)

[3. (Su2022Revealing) Yanfang Su, Weixia Wang, and Xianfang Meng. Revealing the roles of moap1 in diseases: a review. Cells, 11(5):889, March 2022. URL: http://dx.doi.org/10.3390/cells11050889, doi:10.3390/cells11050889. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells11050889)

[4. (Wang2020Bioinformatic) Xuefeng Wang, Shuang Liu, Zhengkai Shao, and Penghai Zhang. Bioinformatic analysis of the potential molecular mechanism of pak7 expression in glioblastoma. Molecular Medicine Reports, 22(2):1362–1372, June 2020. URL: http://dx.doi.org/10.3892/mmr.2020.11206, doi:10.3892/mmr.2020.11206. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2020.11206)